First Study Site of PIPELINE‑RSV International Trial Activated

The recruitment activities for the PIPELINE‑RSV International Trial can officially begin as St George’s University Hospitals NHS Foundation Trust in London, UK, led by PI Dr. Eva Galiza, obtained the first official green light earlier this week.

Recent epidemics have highlighted how infectious disease outbreaks can severely and sometimes uniquely affect the short and longer term health of pregnant women and their infants. Nevertheless, these groups are invariably excluded from pandemic preparedness and response research, as during the COVID-19 pandemic. The overall objective of PIPELINE is to develop a dedicated pregnancy-infant preparedness platform for adaptive trials, to improve pandemic preparedness for these underserved populations.

This international adaptive platform trial is designed to create the largest evidence base to date for evaluating combined Respiratory Syncytial Virus (RSV) prevention strategies. The UK component of the trial will explore whether combining maternal vaccination with infant monoclonal antibodies at four months provides stronger and longer‑lasting protection against RSV than using the RSV maternal vaccine alone. The study at St George’s will contribute to the enrolment target of 1,500 pregnant women across the UK, Switzerland, Belgium, and the Netherlands.

• Read more about this news HERE

• Read more about the RSV Study HERE

• Read more about UNIVR's role in PIPELINE HERE

The PIPELINE project is funded by the European Union under project GA n° 101155852.